Bristol-Myers Squibb Company
BMY
Below: live stock price for Bristol-Myers Squibb Company (BMY), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Bristol-Myers Squibb Company (BMY) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 32,500 people. Over the past year BMY traded between 42.52 and 68.64 USD. Trailing P/E sits near 12.96 on a market cap of about 120.17B USD. It currently yields 4.22% in dividends.
- Prev close
- $59.75
- Volume (24h)
- $679.31M
- Market cap
- $120.17B
- Currency
- USD
Score
56/ 100 · Mixed
- Value37
- Quality84
- Momentum56
- Growth69
- Risk46
- Dividend59
- Liquidity42
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 58.9631 -0.69%
- +20 bars
- 58.4062 -1.62%
- +60 bars
- 58.1922 -1.98%
- +120 bars
- 58.1843 -2.00%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0323 USD.
Interpretation
Composite signals look mixed. Strength: quality with weakness: valuation. Price sits near the lower third of the recent range, trend is sloping downward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value37/100
Value looks weak — driven by PEG (16.64).
P/E:12.96P/B:5.38PEG:16.64 - Quality84/100
Quality looks strong — driven by Gross margin (71.66%).
ROE:46.60%ROA:10.72%Profit margin:18.87%Gross margin:71.66% - Momentum56/100
Momentum looks mixed — driven by 52w change (34.15%).
52w change:34.15% - Growth69/100
Growth looks solid — driven by Earnings growth (153.10%).
Revenue growth:5.70%Earnings growth:153.10% - Risk46/100
Risk looks mixed — driven by Debt / equity (201.86).
Beta:0.18Debt / equity:201.86Short interest:2.25% - Dividend59/100
Dividend looks mixed — driven by Payout ratio (55.29%).
Dividend yield:4.22%Payout ratio:55.29% - Liquidity42/100
Liquidity looks weak — driven by Current ratio (1.53).
Current ratio:1.53Quick ratio:1.29
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 251 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 27.7%
- Max drawdown
- -16.8%
- Below period high
- -13.5%
- Best day
- +7.09%
- Worst day
- -4.07%
- Up days
- 50%
- Current streak
- 2 down
- Typical day swing
- 2.3%
- Volume vs average
- +1%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 68.64 high → 56.15 low · 60 bars
- ResistanceFib +161.8% extensionnot reached88.8488 USD+49.65% from current
- ResistanceFib +100% extensionnot reached81.13 USD+36.65% from current
- ResistanceFib +61.8% extensionnot reached76.3588 USD+28.62% from current
- ResistanceFib +27.2% extensionnot reached72.0373 USD+21.34% from current
- ResistanceFib 23.6% retracementtested 6×65.6924 USD+10.65% from current
- ResistanceFib 38.2% retracementtested 19×63.8688 USD+7.58% from current
- ResistanceFib 50% midpointtested 9×62.395 USD+5.10% from current
- ResistanceFib 61.8% retracementtested 4×60.9212 USD+2.61% from current
- Current59.37 USD
- SupportFib 78.6% retracementNearesttested 6×58.8229 USD-0.92% from current
- SupportFib −27.2% extensionnot reached52.7527 USD-11.15% from current
- SupportFib −61.8% extensionnot reached48.4312 USD-18.42% from current
- SupportFib −100% extensionnot reached43.66 USD-26.46% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $68.64
- 52w low
- $42.52
- 52w change
- 34.15%
- Day high
- $59.87
- Day low
- $58.44
- P/E (TTM)
- 12.96
- Forward P/E
- 8.88
- PEG
- 16.64
- Price / Book
- 5.38
- Beta (5Y)
- 0.18
- Enterprise value
- 154.16B
- EV / Revenue
- 3.13
- EV / EBITDA
- 8.14
- EPS (TTM)
- $4.54
- Forward EPS
- $6.62
- Dividend yield
- 4.22%
- Dividend rate
- $2.52
- Payout ratio
- 55.29%
- Revenue (TTM)
- 49.19B
- EBITDA
- 18.93B
- Free cash flow
- 8.11B
- Total cash
- 11.07B
- Total debt
- 45.05B
- Debt / Equity
- 201.86
- Current ratio
- 1.53
- Quick ratio
- 1.29
- Profit margin
- 18.87%
- Gross margin
- 71.66%
- Return on assets
- 10.72%
- Return on equity
- 46.60%
- Shares outstanding
- 2.04B
- Float
- 2.04B
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Analyst & Risk
- Beta (vs S&P 500)
- 0.18
- very stable
- 52-week change
- 34.15%
- Short % of float
- 2.25%
- Short ratio (days)
- 3.99
- Debt / Equity
- 201.86
- very high leverage
- Current ratio
- 1.53
- Quick ratio
- 1.29
- ROE
- 46.60%
- ROA
- 10.72%
- PEG ratio
- 16.64
- richly valued
- EV / Revenue
- 3.13
- EV / EBITDA
- 8.14
- Revenue growth
- 5.70%
- Earnings growth
- 153.10%
- EBITDA
- 18.93B
- Free cash flow
- 8.11B
- Total cash
- 11.07B
- Total debt
- 45.05B
- Insider holdings
- 0.10%
- Institutional
- 84.89%
Recent rating changes
- 2026-10-13Wells FargoEqual-Weight → Equal-Weightmain
- 2026-10-08Cantor FitzgeraldNeutral → Neutralmain
- 2026-10-07Morgan StanleyUnderweight → Underweightmain
- 2026-10-05Leerink PartnersOutperform → Market Performdown
- 2026-09-16Piper SandlerOverweight → Overweightreit
- 2026-09-10HSBCHold → Holdmain
- 2026-08-05Argus ResearchHold → Buyup
- 2026-08-03CitigroupNeutral → Neutralmain
Financial documents
- Corporate Changes & Voting Matters8-K2026-07-30
- Annual report of employee stock purchase11-K2026-06-05
- Offering RegistrationsS-82026-05-08
- Periodic Financial Reports10-Q2026-04-30
- Proxy StatementsDEFA14A2026-04-17
- Notice of termination of registration of a class of securities under Section 12(g)15-12G2026-03-27
- Annual Report to ShareholdersARS2026-03-25
- Periodic Financial Reports10-K2026-02-11
- Corporate Changes & Voting Matters8-K2026-02-05
- Corporate Changes & Voting Matters8-K2026-01-12
- Corporate Changes & Voting Matters8-K2025-11-18
- Corporate Changes & Voting Matters8-K2025-11-10
Recent news
- Better Dividend Stock: Merck vs. Bristol Myers SquibbTIKR5h ago
- Better Dividend Stock for Retirees: Bristol Myers Squibb vs. CVS HealthTIKR5h ago
- Bristol Myers Squibb (BMY) Heads To ESMO 2026 With New Oncology DataSimply Wall St.5h ago
- How Much Upside Is Left In Regeneron Stock?Trefis9h ago
- What Has Changed About Owning Gilead Stock?Trefis11h ago
- Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow24/7 Wall St.11h ago
- Bristol-Myers Squibb Seen Beating Q3 Revenue Estimates, RBC SaysMT Newswires12h ago
- AbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying?Insider Monkey13h ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,421 USD-1.64%
- 7203.TToyota Motor Corporation3,093 USD-0.29%
- 9984.TSoftBank Group Corp.4,562 USD-5.84%
- 6758.TSony Group Corporation3,946 USD-0.35%
- 6861.TKeyence Corporation80,490 USD-1.13%
- NVDANVIDIA Corporation217.09 USD+1.38%
- AAPLApple Inc.342.94 USD-0.15%
- GOOGLAlphabet Inc.344.18 USD+1.05%
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.